bluebird bio Announces First Patient Transplanted in Phase 1/2...

"We welcome the start of the Northstar Study, the second beta thalassemia major trial initiated by bluebird bio with our LentiGlobin gene therapy product candidate" "We are very excited to have reached this critical milestone today with the infusion of modified blood stem cells in our patient with thalassemia.

http://ift.tt/P5xjQF